Gross Profit Increased 29.6% Year-Over-Year to Approximately $2.0 Million in Q1 2026  Commercial Real Estate Brokerage Revenue Increased 379.3% Year-Over-Year to $273 Thousand in Q1 2026 Loss from Operations Improved 46.5% Year-Over-Year To $2.5 Million, Compared To $4.7 Million in the Prior-Year Period CELEBRATION, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) — La Rosa Holdings Corp. (NASDAQ: LRHC) (“La Rosa” or the “Company”), a real estate and PropTech company, today provided a business update and reported financial results for the first quarter ended March 31, 2026. Q1 2026 Financial HighlightsReal Estate Brokerage Services (Commercial) revenue increased by approximately $216 thousand to $273 thousand, or approx. 379.3% for the first quarter ended March 31, 2026 from $57 thousand for the first quarter ended March 31, 2025 Title Settlement...

Board Declares Quarterly Dividend of $0.25 per Share Revenue of $69.5 Million Net Income Attributable to Cohen & Company Inc. of $3.6 Million, or $0.94 per Diluted Share Adjusted Pre-Tax Income of $10.1 Million, or $1.62 per Diluted Share PHILADELPHIA and NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) — Cohen & Company Inc. (NYSE American: COHN) (“Cohen & Company” or the “Company”) today reported financial results for its second quarter ended June 30, 2026. Lester Brafman, Chief Executive Officer of Cohen & Company, said, “We are pleased to deliver another solid quarter, driven by continued strong performance in our full-service boutique investment bank, Cohen & Company Capital Markets, and its expertise in SPAC and de-SPAC transactions. Recently, we achieved important milestones across our sponsored SPACs, with...

Barcelona-based Tech Company sustains profitability through the first half of 2026, with gross margin up 9.3 points year-on-year and a record second quarter. BARCELONA, Spain, Aug. 03, 2026 (GLOBE NEWSWIRE) — Stark Future, the Barcelona-based premium electric-motorcycle manufacturer, today reported revenue of €86.0 million for the first half of 2026, up 46% year-on-year, and confirmed the business was both EBITDA- and EBIT-positive for the period, an important marker of the quality, not just the pace, of its growth.EBITDA reached €5.3 million, a 6.1% margin, compared with a €1.7 million loss in the same period last year, a swing of roughly €7 million. Gross margin improved 9.3 percentage points year-on-year to 39.6%, with per-unit bike costs falling as volumes scaled. The company delivered 8,124 motorcycles in the half, 45% more...

Company to hold a conference call at 8:30 a.m. ET DURHAM, N.C., Aug. 03, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it will report second quarter 2026 financial results on Thursday, August 13, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern Time.Details for the conference call can be found below:   Date: Thursday, August 13, 2026Time: 8:30 a.m. Eastern TimeToll Free: 1-877-451-6152International: 1-201-389-0879Conf.ID: 13761132   Call.Me: Participants can use the dial-in numbers above or click the CallMe link for instant telephone access to the event. The CallMe link will be...

RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027  Patient dosing initiated in Phase 1 multiple-ascending dose trial of DT-818 in myotonic dystrophy type 1 Cash and securities of $207.4 million at quarter-end provide strong financial runway CARLSBAD, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported second quarter 2026 financial results and highlighted business updates and upcoming milestones across its GeneTAC® portfolio. “Design continued its strong operational execution in the second quarter building on the positive RESTORE-FA data reported in May. Those four-week data demonstrated the...

Driven by positive momentum in rental growth and disciplined capital management Key Highlights2H FY2026 distribution per unit (“DPU”) of 1.85 cents brought full-year DPU to 3.70 cents, representing a full-year increase of 3.0% YoY, supported by recurring earnings from a strong portfolio of operational assets in Singapore. Net property income (“NPI”) grew 6.6% YoY for 2H FY2026 driven by the acquisition of PLQ Mall and performance from the Singapore retail assets, partially offset by the divestment of Jem office. Lower weighted average cost of debt1 at 2.75% per annum with the interest coverage ratio (“ICR”)2 increased to 2.1 times3. Gearing ratio of 38.9% remains at a prudent level. Strong retail portfolio committed occupancy of 98.5%. Positive retail rental reversion of 11.7%4 achieved. Tenant sales grew 24.0%5 in FY2026. On a like‑for‑like...

Ocular’s AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026 FDA Type C Meeting Minutes Formalize SOL-1 Trial with Confirmatory Evidence as Sufficient to Support Submission of AXPAXLI NDA in wet AMD AXPAXLI NDA submission to be based on SOL-1 Week 52 efficacy and safety data, interim SOL-R safety data, and confirmatory evidence Pre-NDA meeting scheduled with FDA in Q3 2026 with the NDA submission to follow the Section 505(b)(2) pathway which could accelerate the review timeline by up to 60 days New Post Hoc SOL-1 analysis demonstrates up to an estimated 72% reduction in treatment burden over 60 weeks with AXPAXLI as compared to a projected on-label aflibercept (2 mg) dosing schedule of every 8 weeks Commercial readiness accelerating ahead of a potential 2027 launch Cash...

BAYONNE, N.J., Aug. 03, 2026 (GLOBE NEWSWIRE) — BCB Bancorp, Inc. (the “Company”), (NASDAQ: BCBP), the holding company for BCB Community Bank (the “Bank”), today reported a net loss of $14.8 million for the second quarter of 2026, compared to net income of $4.9 million in the first quarter of 2026, and net income of $3.6 million for the second quarter of 2025. The Company’s loss per diluted share for the second quarter was ($0.85) compared to earnings per diluted share of $0.26 in the preceding quarter and $0.18 in the second quarter of 2025. The Company’s reported net loss for the six months ended June 30, 2026 was $9.9 million, compared to a net loss of $4.8 million for the six months ended June 30, 2025. The Company’s loss per diluted share for the six months ended June 30, 2026 was ($0.60) compared to a loss per diluted share...

Second Quarter 2026 HighlightsRevenue increased 19% to €378 million Loss for the period of €4 million, 0.9% as a percentage of revenue with increased operating results offset by unrealized foreign currency losses Adjusted EBITDA1 increased 19% to €76 million and Adjusted EBITDA margin1 expanded to 20.2% Net cash from operating activities increased 20% to €117 million and Free cash flow1 increased 14% to €59 million Repurchased $140 million of shares during the quarter under the share repurchase plan Upsized revolving credit facility to €250 million, lowering fees and extending maturity to 2031 Entered into strategic partnerships with leading prediction market exchanges, expanding total addressable marketST. GALLEN, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) — Sportradar Group AG (Nasdaq: SRAD) (“Sportradar” or the “Company”),...

$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the quarter with $1.1 billion in cash and investments PITTSBURGH, Aug. 03, 2026 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company” or “Krystal”) (NASDAQ: KRYS) today reported financial results for the second quarter ended June 30, 2026 and provided a business update. “Our second quarter reflects the strength of the Krystal model: a global commercial product that continues to perform, a strong balance sheet, and a pipeline now moving toward multiple registrational readouts,” said Krish S. Krishnan, Chairman and Chief Executive Officer of Krystal Biotech. “VYJUVEK is not only changing the standard of care for DEB patients...